Sensitivity of the Enzygnost anti-EBV/IgG for the determination of the Epstein-Barr virus immune status in pediatric patients.
The Enzygnost Anti-EBV/IgG shows good performance for populations not defined by age. Samples from 349 pediatric outpatients were screened with the assay and with immunofluorescence assay (IFA) as the gold standard. The Enzygnost assay showed a sensitivity of 85%. Ten and one-tenth percent of EBV seropositive samples were classified as intermediate, and 4.9% were falsely determined as seronegative when compared to the standard IgG anti-virus capsid antigen (VCA) IFA. Our data suggest a limited sensitivity of the assay with samples from pediatric patients.
Kleines
Michael
M
Division of Virology, Department of Medical Microbiology, UK Aachen, RWTH Aachen, 52074 Aachen, Germany. mkleines@ukaachen.de
Scheithauer
Simone
S
Ritter
Klaus
K
Häusler
Martin
M
D000293:Adolescent; D000956:Antigens, Viral / Q000276:immunology*; D036022:Capsid Proteins / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D019084:Fluorescent Antibody Technique, Indirect; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D008403:Mass Screening; D011933:Reagent Kits, Diagnostic / Q000821:virology; D012680:Sensitivity and Specificity; D012698:Serologic Tests / Q000379:methods
D000956:Antigens, Viral; D036022:Capsid Proteins; C041788:Epstein-Barr viral capsid antigen; D007074:Immunoglobulin G; D011933:Reagent Kits, Diagnostic